tbuckley/cabot-search huggingface dataset:
Adjuvant Treatment of Early Ovarian Clear Cell Carcinoma: A Population-Based Study of Whole Abdominal Versus Pelvic Nodal Radiotherapy
Authors: Soumyajit Roy, Paul Hoskins, Anna Tinker, Harinder Brar, Gale Bowering, Gaurav Bahl
Journal: Journal of the National Comprehensive Cancer Network (2021)

Adjuvant treatment in early ovarian clear cell carcinoma (OCCC) is not yet standardized. The objective of this population-based study was to compare the outcome of patients with early OCCC treated with adjuvant chemotherapy versus chemoradiotherapy (chemoRT) and evaluate the association of adjuvant radiotherapy regimens (whole abdominal radiotherapy [WART] versus pelvic nodal radiotherapy [PRT]) with outcome.Chart review was conducted to identify patients with stage I and II OCCC with complete information on staging. Patients with stage IA, IB, or IC OCCC purely resulting from capsular rupture were excluded because the provincial protocol does not recommend adjuvant treatment.Overall, 403 patients were identified and 343 received adjuvant treatment, of whom 255 had stage IC or II OCCC and 153 were eligible for final analysis. On Cox multivariable regression, receipt of chemoRT (n=90) was associated with an improvement in failure-free survival (FFS) (hazard ratio [HR], 0.57; 95% CI, 0.34-0.94) compared with chemotherapy alone (n=63). Use of chemoRT also resulted in 54% reduction in the cumulative incidence of cancer-specific mortality (subdistribution HR, 0.46; 95% CI, 0.24-0.89). However, there was no significant difference in the HR for overall survival (OS) between the chemoRT (HR, 0.70; 95% CI, 0.43-1.13) and chemotherapy group. Relative to chemotherapy + WART (chemo-WART), chemotherapy + PRT (chemo-PRT) was not associated with any significant difference in HR for FFS (HR, 1.34; 95% CI, 0.40-4.44) or OS (HR, 1.13; 95% CI, 0.37-3.46).Adjuvant chemoRT was associated with a lower risk of failure compared with chemotherapy alone. However, there was no difference in OS between the adjuvant chemotherapy and chemoRT regimens. Additionally, no significant difference in terms of FFS or OS was found between the chemo-WART and chemo-PRT groups.
443P First-line chemotherapy with raltitrexed in metastatic colorectal cancer: An AGEO multicentre study
Authors: C. Gallois, E. Hafliger, E. Auclin, A. Perret, P. Artru, C. Coutzac, A. Turpin, A. Pellat, V. Randrian, D. Basile, R. Faroux, C. Locher, V. Hautefeuille, O. Dubreuil, L-J. Palmieri, M. Dior, J. Taieb
Journal: Annals of Oncology (2020)
429P Feasibility and toxicity of hypofractionated radiotherapy (5x5 Gy) with a simultaneous integrated boost (5x6 Gy) in locally advanced rectal cancer
Authors: M. Temnyk, K. Pędziwiatr, P. Pawłowski, M. Gidzińska-Wielgosz, M. Chojnacka, L. Wyrwicz
Journal: Annals of Oncology (2020)
1056P Durvalumab (D) in combination with chemoradiotherapy (CRT) in solid tumours: Phase I CLOVER study
Authors: J.E. Bauman, S.D. Karam, M. Nishio, M-J. Ahn, D-W. Kim, S-W. Kim, H. Murakami, L. Wang, J. Shetty, K.Y. Wu, P.A. Dennis, B.C. Cho
Journal: Annals of Oncology (2020)
1717P Behavioral practices of cancer patients during COVID-19 pandemic: A Middle East and North Africa Study
Authors: A.R. Jazieh, Z. Benbrahim, S. Al-Sukhun, A.M. Abusanad, M.O. Alorabi, A.R.A.D. El Kinge, E. Tashkandi, M.A.M.A. AlNassar, A. Bensalem, A.A. Alsharm, H. Errihani, A. Bounedjar, C. Mazouzi, M.O.F. Alkaiyat, H. Jradi, N. Abdelhafiz
Journal: Annals of Oncology (2020)
CN27 Value of nurse navigators (NNs) telemonitoring for cancer patients (pts) tested positive for COVID-19
Authors: D. Mathivon, M. Abbas, A. Barrais, A. Duflot-Boukobza, M. Ferrua, J. Legendre, C. Mendes, M. Merad, E. Minvielle, O. Mir, M. Pons, F. Scotté
Journal: Annals of Oncology (2020)
1744P COVID-19 in cancer patients: Risk factors for the development of severe clinical event (SCE)
Authors: J.J. Serrano Domingo, E. Corral de la Fuente, R. Martin Huertas, E.M. Vida Navas, J.J. Soto Castillo, L. Sanz Gomez, J. Torres Jimenez, J. Esteban Villarrubia, I. Orejana Martin, P. Alvarez Ballesteros, J. Pozas Perez, M.V. San Roman Gil, P. Garrido Lopez, A. Carrato Mena
Journal: Annals of Oncology (2020)
1982P Fibroblasts-derived matrices confer resistance to oxaliplatin and cetuximab in a snail-dependent way in CRC
Authors: C. Galindo Pumariño, J. Villalón López, J. Barquín, C. De la Pinta Alonso, M. Rodriguez, F. Longo, P. Reguera Puertas, E. Romio de las Heras, C. Perna, A. Carrato Mena, C. Peña
Journal: Annals of Oncology (2020)
1372P Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) after failure of previous immune checkpoint inhibitor therapy (ICIs): Updated results from the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
Authors: C. Grohé, W. Gleiber, S. Haas, S. Hammerschmidt, S. Krüger, H. Mueller-Huesmann, M. Schulze, T. Wehler, J. Atz, R. Kaiser
Journal: Annals of Oncology (2020)
491P Neoadjuvant nivolumab in early stage colorectal cancer
Authors: A. Avallone, A. De Stefano, U. Pace, A. Catteau, E. Di Gennaro, F. Tatangelo, I. Boquet, A. Cassata, S. Costantini, S. De Franciscis, F. Collina, N. Zanaletti, C. Vitagliano, V. Granata, D. Giannarelli, S. Lastoria, P.A. Ascierto, J. Galon, P. Delrio, A. Budillon
Journal: Annals of Oncology (2020)
536MO A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours
Authors: A.A. Adjei, M. Beg, J. Melear, J. Thompson, F.Y-C. Tsai, J.C. Baranda, B. Bastos, A. Spira, Y. Lou, M. Seetharam, M. Uemura, D.R. Camidge, N. Yamamoto, C.L. Cowey, T. Doi, S.P. Anthony, M. Janat-Amsbury, M. Wade, D.J. Bearss, J. Sarantopoulos
Journal: Annals of Oncology (2020)
1576P Marital status and sexual health in breast cancer survivors: A cross-sectional study
Authors: A.L.V. Matos, S. Teixeira, S. Ponte, V. Fonseca, L. Fernandes, J.A. Graca, M.T. Neves, F. Alves, A. Plácido, H. Miranda, A. Martins
Journal: Annals of Oncology (2020)
Abstract P211: Prediction of Stroke in a Population with High Prevalence of Diabetes: The Strong Heart Study
Authors: Ying Zhang, Wenyu Wang, Elisa T Lee, Thomas K Welty, Jorge R Kizer, Richard B Devereux, Nawar M Shara, Lyle G Best, Julie A Stoner, Jeunliang Yeh, Barbara V Howard
Journal: Circulation (2013)

Background— Stroke prediction models are valuable to physicians in evaluating the risk of their patients so that preventive interventions can be promoted. The Framingham Risk Profile is a widely used stroke prediction equation. However, the contributions of some common risk factors for stroke vary across populations and some risk factors are specific to certain populations. For example, albuminuria is an important risk factor in American Indians (AIs), which is not included in the Framingham equation. The objective of the current study is to develop stroke prediction equations using routinely collected variables in AIs, a population with high rates of diabetes and stroke. Methods— The data used in the analysis are from 4507 stroke free participants at enrollment in the Strong Heart Study (SHS), the largest population-based longitudinal study of cardiovascular disease (CVD) and its risk factors in AIs in Arizona, Oklahoma, and South/North Dakota. As of December 2008, 379/4507 (8.4%) participants suffered a first stroke during an average follow-up of 17 years. Baseline potential risk factors were included in the Cox proportional-hazard models to develop gender-specific prediction equations. Backward selection was used to choose the predictors. Model performance was assessed using Harrell’s C statistics based on bootstrapping methods. Results— Baseline age, untreated systolic blood pressure, treated diastolic blood pressure, HDL-C, current smoking, diabetes, macro-albuminuria, and history of CVD are significant predictors for incident stroke among women. Most of these predictors except HDL-C were also in the prediction equation for men. The equations provided good discrimination ability, as indicated by a C statistic of 0.72 for men and 0.73 for women. Conclusions— Predicted risk of stroke in 10 years can be provided for physicians and their patients. Then appropriate intervention can be implemented. The stroke prediction equations from SHS can be applied to other AIs as well as other ethnic groups with high rates of diabetes and albuminuria.
Pressure-induced amorphous zeolitic imidazole frameworks with reduced toxicity and increased tumor accumulation improves therapeutic efficacy In vivo
Authors: Zhenqi Jiang, Yanying Li, Zhenni Wei, Bo Yuan, Yinjie Wang, Ozioma Udochukwu Akakuru, Yong Li, Juan Li, Aiguo Wu
Journal: Bioactive Materials (2020)

Zeolitic Imidazole Frameworks (ZIFs) are widely applied in nanomedicine for their high drug loading, suitable pore size, pH-responsive drug release, and so on. However, fast drug release during circulation, unexpected toxicity to mice major organs, undesirable long-term accumulation in the lung and even death currently hinder their in vivo biomedical applications. Herein, we report an amorphous ZIF-8 (aZIF-8) with high loading of 5-Fu through pressure-induced amorphization. This nano-system avoids early drug release during circulation and provides tumor microenvironment-responsive drug release with improved in vitro cell viability, and survival rate in in vivo evaluations as compared to ZIF-8. Furthermore, aZIF-8 shows longer blood circulation and lower lung accumulation than ZIF-8 at same injected doses. Less drug release during circulation, longer blood circulation, and better biocompatibility of aZIF-8/5-Fu significantly improves its therapeutic efficacy in ECA-109 tumor-bearing mouse, and result in 100% survival rate over 50 days after treatment. Therefore, aZIF-8 with favorable biocompatibility and long blood circulation is expected to be a promising nano-system for efficacious cancer therapy in vivo.
525O A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
Authors: G. Ku, J.C. Bendell, A.W. Tolcher, S.A. Hurvitz, A. Krishnamurthy, A.B. El-Khoueiry, A. Patnaik, R.T. Shroff, A. Noonan, N.M. Hahn, M. Matrana, M. Zettl, K. Aviano, L. Mar, P. Jolicoeur, S. Olwill, I. Bruns, S. Piha-Paul
Journal: Annals of Oncology (2020)
472P Whole genome sequencing of metastatic CRC reveals footprints from the past and present with future clinical relevance
Authors: P.A.J. Mendelaar, M. Smid, J. Van Riet, L. Angus, H.J.G. Van de Werken, M. Labots, N. Steeghs, M.P. Hendriks, G.A. Cirkel, J.M. van Rooijen, A.J. ten Tije, M.P. Lolkema, E. Cuppen, S. Sleijfer, J.W.M. Martens, S.M. Wilting
Journal: Annals of Oncology (2020)
557P Binimetinib, pemetrexed (Pem) and cisplatin (Cis), followed by maintenance of Binimetinib and Pem in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations: The phase Ib SAKK 19/16 trial
Authors: P.R. Froesch, M.T. Mark, S.I. Rothschild, Q. Li, G. Godar, C. Rusterholz, S. Schmid, I. Colombo, Y. Metaxas, H.E. Thut, C. Sessa, O. Gautschi, M. Früh
Journal: Annals of Oncology (2020)
828P Expected versus observed response to platinum-based chemotherapy after poly (ADP-ribose) polymerase inhibitor treatment for relapsed ovarian cancer
Authors: T. Baert, B. Ataseven, M. Bommert, N. Concin, J. Frindte, S. Schneider, P. Harter, A. du Bois, F. Heitz
Journal: Annals of Oncology (2020)
1439P Phase II study to evaluate feasibility and safety of oral nutritional supplementation with high density liquid diet after total gastrectomy for patients with gastric cancer
Authors: T. Yamada, T. Hayashi, H. Fujikawa, Y. Kumazu, S. Nagasawa, M. Nakazono, K. Kano, K. Hara, H. Watanabe, K. Komori, Y. Shimoda, K. Takahashi, T. Ogata, T. Oshima, T. Yoshikawa
Journal: Annals of Oncology (2020)
<i>Panax notoginseng</i> saponins modulate the gut microbiota to promote thermogenesis and beige adipocyte reconstruction <i>via</i> leptin-mediated AMPKα/STAT3 signaling in diet-induced obesity
Authors: Yu Xu, Ning Wang, Hor-Yue Tan, Sha Li, Cheng Zhang, Zhangjin Zhang, Yibin Feng
Journal: Theranostics (2020)

Background: Activation of the thermogenic program in white and brown adipocytes presents a promising avenue for increasing energy expenditure during the treatment of obesity. The endogenous mechanism for promoting thermogenesis in brown adipocytes or browning in white adipocytes has indicated that the gut microbiota is a crucial regulator of the host energy balance. However, whether the effects of the therapeutic intervention-induced modulation of the gut microbiota on adipocyte browning involved the regulation of leptin remains unclear. Method: The adipose features were analyzed by body composition analysis, infrared camera observations, transmission electron microscopy and H&E staining. The gene and protein expression in adipose tissue were detected by qRT-PCR, immunoblotting, immunohistochemistry and immunofluorescence staining. The gut microbiome signature was identified by 16S rRNA gene amplicon sequencing, and both mice with high-fat diet-induced obesity (DIO) and mice with antibiotics-induced microbiome depletion were subjected to fecal microbiota transplantation. Results: Treatment with Panax notoginseng saponins (PNS) shaped the murine gut microbiome by increasing the abundances of Akkermansia muciniphila and Parabacteroides distasonis, and as a result, DIO mice harbored a distal gut microbiota with a significantly increased capacity to reduce host adiposity. The PNS-induced modulation of the gut microbiota in DIO mice could increase brown adipose tissue (BAT) thermogenesis and beige adipocyte reconstruction by activating the leptin-AMPK/STAT3 signaling pathway, which results in the promotion of energy expenditure. Leptin has an essential influence on the anti-obesity effects of PNS. In cases of leptin deficiency, the PNS-induced modulation of the gut microbiota exerts negative effects on thermogenesis and browning in white adipose tissue (WAT), which indicates that PNS fail to reduce obesity in leptin gene-deficient mice. The PNS-induced modulation of the gut microbiota exerted a minimal effect on DIO mice with antibiotic-induced microbiome depletion, which confirmed the correlation between altered gut microbiota and the remodeling of adipose tissues in DIO mice. The direct influence of leptin on browning via the AMPKα/STAT3 signaling pathway in C3H101/2 cells supported our in vivo results that signalling through the leptin-AMPK/STAT3 pathway induced by the PNS-modulated gut microbiota was involved in beige adipocyte reconstruction. Conclusion: Our results revealed that leptin signaling is critical for alterations in microbiota-fat crosstalk and provide promising avenues for therapeutic intervention in the treatment of obesity.
739P Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immuno-oncology: A real-world study on behalf of Meet-URO group (MeetUro-7b)
Authors: M. Stellato, D. Santini, E. Verzoni, U. De Giorgi, C. Casadei, S. Buti, M. Maruzzo, V. Murianni, A. Sbrana, G. Di Lorenzo, C. Anesi, M. Sorarù, E. Naglieri, R. De Vivo, F. Vignani, F. Grillone, C. Mucciarini, G. Roviello, S. Pignata, G. Procopio
Journal: Annals of Oncology (2020)
105P Dynamic change in blood derived variant allele frequency as a predictive marker for response from checkpoint inhibitor based therapies among metastatic solid tumours
Authors: S. Kato, B. Li, S.W. Cha, D. Bianchi-Frias, N. Kamei, R. Hoiness, J. Hoo, P.N. Gray, T. Iyama, M. Kashiwagi, H-M. Lu, R. Kurzrock
Journal: Annals of Oncology (2020)
176P Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)
Authors: J. Hauke, C. Ernst, P.A. Fasching, C. Jackisch, F. Seither, P. Klare, K.E. Rhiem, S. Schmatloch, J. Huober, A. Stefek, S. Seiler, C. Uleer, G. Doering, A. Schneeweiss, C. Denkert, M. Untch, J-U. Blohmer, R.K. Schmutzler, S. Loibl, E. Hahnen
Journal: Annals of Oncology (2020)
1429P Phase II trial of perioperative mdcf + avelumab in locally advanced gastroesophageal adenocarcinoma: Safety/efficacy
Authors: T. Alcindor, T. Opu, C. Mueller, M. Hickeson, V. Marcus, S. Camilleri-Broet, P-O. Fiset, G. Artho, Z. Koulouris, J. Cools-Lartigue, L. Ferri
Journal: Annals of Oncology (2020)
LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
Authors: N. Colombo, A. Gadducci, J. Sehouli, E. Biagioli, G-B. Nyvang, S. Riniker, A. Montes, N. Ottevanger, A.G.G. Zeimet, I.B. Vergote, G. Funari, A. Baldoni, G. Tognon, A. De Censi, C. Churruca Galaz, R. Chekerov, J. Maenpaa, E. Rulli, R. Fossati, A. Poveda
Journal: Annals of Oncology (2020)
EZH2-Targeted Therapies in Cancer: Hype or a Reality
Authors: Marie-Lisa Eich, Mohammad Athar, James E. Ferguson, Sooryanarayana Varambally
Journal: Cancer Research (2020)

Abstract Next-generation genomic sequencing has identified multiple novel molecular alterations in cancer. Since the identification of DNA methylation and histone modification, it has become evident that genes encoding epigenetic modifiers that locally and globally regulate gene expression play a crucial role in normal development and cancer progression. The histone methyltransferase enhancer of zeste homolog 2 (EZH2) is the enzymatic catalytic subunit of the polycomb-repressive complex 2 (PRC2) that can alter gene expression by trimethylating lysine 27 on histone 3 (H3K27). EZH2 is involved in global transcriptional repression, mainly targeting tumor-suppressor genes. EZH2 is commonly overexpressed in cancer and shows activating mutations in subtypes of lymphoma. Extensive studies have uncovered an important role for EZH2 in cancer progression and have suggested that it may be a useful therapeutic target. In addition, tumors harboring mutations in other epigenetic genes such as ARID1A, KDM6, and BAP1 are highly sensitive to EZH2 inhibition, thus increasing its potential as a therapeutic target. Recent studies also suggest that inhibition of EZH2 enhances the response to tumor immunotherapy. Many small-molecule inhibitors have been developed to target EZH2 or the PRC2 complex, with some of these inhibitors now in early clinical trials reporting clinical responses with acceptable tolerability. In this review, we highlight the recent advances in targeting EZH2, its successes, and potential limitations, and we discuss the future directions of this therapeutic subclass.
413P Risk factors for recurrence in patients with high-risk stage II colon cancer after curative resection
Authors: H. Ohge, S. Sadahiro, K. Sakamoto, T. Tsuchiya, T. Takahashi, T. Sato, K. Kondo, Y. Ogata, H. Baba, M. Itabashi, M. Ikeda, M. Hamada, M. Kusano, I. Hyodo, J. Sakamoto, M. Taguri, S. Morita
Journal: Annals of Oncology (2020)
288P Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
Authors: D.W. Miles, E.M. Ciruelos, A. Schneeweiss, F. Puglisi, T. Peretz-Yablonski, M. Campone, I. Bondarenko, Z. Nowecki, H. Errihani, S. Paluch-Shimon, A.M. Wardley, J.L. Merot, Y. du Toit, D. Klingbiel, V. Revelant, T. Bachelot
Journal: Annals of Oncology (2020)
Long-term outcomes for adults with chronic granulomatous disease in the United Kingdom
Authors: Luiza C. Campos, Giulia Di Colo, Vruti Dattani, Helen Braggins, Dinakantha Kumararatne, Anthony P. Williams, Hana Alachkar, Stephen Jolles, Alexandra Battersby, Theresa Cole, Suzanne Elcombe, Kimberly C. Gilmour, David Goldblatt, Andrew R. Gennery, Jamanda Haddock, David M. Lowe, Siobhan O. Burns
Journal: Journal of Allergy and Clinical Immunology (2020)
450P The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC): Updated analysis
Authors: T. Kawakami, K. Yamazaki, H. Go, T. Masuishi, Y. Kawamoto, K. Kato, R. Kumanishi, K. Sawada, H. Shirasu, S. Yuki, K. Yamamoto, T. Yamanaka, Y. Komatsu, K. Muro, H. Yasui
Journal: Annals of Oncology (2020)
1124P Phase Ib study to evaluate the safety of selinexor (SEL) in combination with pembrolizumab (PEM) in patients with advanced malignancies- the: The melanoma experience
Authors: I.C. Glitza, S. Patel, A. Zarifa, C.H. Leung, H. Lin, L. McQuinn, J. Gong, B. Yilmaz, J. Chambers, S. Sulovic, I. John, T. Hennegan, S. Fu, A.M. Tsimberidou, F. Janku, D.D. Karp, F. Meric-Bernstam, A. Naing
Journal: Annals of Oncology (2020)
1971P Neuroendocrine (NE) expression profiling in non-castrate tumours is associated with poor therapy benefit and adverse clinical outcome in metastatic castration-resistant prostate cancer (mCRPC) patients
Authors: N. Jimenez, O. Reig, G. Castellano, M. Orrillo, L. Ferrer-Mileo, H.K. Oberoi, D. Pesántez, A. Font, M. Domènech, A. Rodríguez-Vida, J. Carles, C. Suárez, N. Sala-González, L. Rodríguez-Carunchio, S. Díaz, A. Prat, M. Marín-Aguilera, B. Mellado
Journal: Annals of Oncology (2020)
1096P Clinicopathologic risk factors for large cell transformation in patients with Sezary syndrome
Authors: R. Bardhi, N.K. Jairath, R. Jairath, J. Runge, R. Bledea, A. Hristov, R. Wilcox, L.C. Tsoi, M. Patrick, T. Tejasvi
Journal: Annals of Oncology (2020)
Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor–Positive Breast Cancers
Authors: Andrea M. Pesch, Nicole H. Hirsh, Benjamin C. Chandler, Anna R. Michmerhuizen, Cassandra L. Ritter, Marlie P. Androsiglio, Kari Wilder-Romans, Meilan Liu, Christina L. Gersch, José M. Larios, Lori J. Pierce, James M. Rae, Corey W. Speers
Journal: Clinical Cancer Research (2020)

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have improved progression-free survival for metastatic, estrogen receptor-positive (ER+) breast cancers, but their role in the nonmetastatic setting remains unclear. We sought to understand the effects of CDK4/6 inhibition (CDK4/6i) and radiotherapy in multiple preclinical breast cancer models.Transcriptomic and proteomic analyses were used to identify significantly altered pathways after CDK4/6i. Clonogenic assays were used to quantify the radiotherapy enhancement ratio (rER). DNA damage was quantified using γH2AX staining and the neutral comet assay. DNA repair was assessed using RAD51 foci formation and nonhomologous end joining (NHEJ) reporter assays. Orthotopic xenografts were used to assess the efficacy of combination therapy.Palbociclib significantly radiosensitized multiple ER+ cell lines at low nanomolar, sub IC50 concentrations (rER: 1.21-1.52) and led to a decrease in the surviving fraction of cells at 2 Gy (P < 0.001). Similar results were observed in ribociclib-treated (rER: 1.08-1.68) and abemaciclib-treated (rER: 1.19-2.05) cells. Combination treatment decreased RAD51 foci formation (P < 0.001), leading to a suppression of homologous recombination activity, but did not affect NHEJ efficiency (P > 0.05). Immortalized breast epithelial cells and cells with acquired resistance to CDK4/6i did not demonstrate radiosensitization (rER: 0.94-1.11) or changes in RAD51 foci. In xenograft models, concurrent palbociclib and radiotherapy led to a significant decrease in tumor growth.These studies provide preclinical rationale to test CDK4/6i and radiotherapy in women with locally advanced ER+ breast cancer at high risk for locoregional recurrence.
1307P Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts) from blood first assay screening trial (BFAST) and comparison with real-world data (RWD)
Authors: R. Dziadziuszko, Q. Zhang, X. Li, S.M. Paul, M. Sugidono, S. Mocci, A. Kinkolykh, D.S. Shames, V. Archer, M.S. Mathisen, D.X. Jin, S.M. Gadgeel, S. Peters, T. Mok
Journal: Annals of Oncology (2020)
1898P A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: JME-001
Authors: N. Fujimoto, T. Kozuki, K. Aoe, Y. Miyamoto, S. Wada, D. Harada, M. Yoshida, J. Sakurai, K. Hotta
Journal: Annals of Oncology (2020)